Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.39 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18411800 | 0.90 | KDM4E (0.50) | KDM4ELMNAALDH1A1HSD17B10MAPT | |
| SCHEMBL22480889 | 0.88 | KDM4E (0.50) | KDM4ELMNAALDH1A1HSD17B10MAPT | |
| SCHEMBL7383587 | 0.87 | KDM4E (0.57) | KDM4ELMNAALDH1A1HSD17B10MAPT | |
| SCHEMBL15858102 | 0.87 | KDM4E (0.61) | KDM4ELMNAALDH1A1HSD17B10MAPT | |
| SCHEMBL15858093 | 0.87 | CYP17A1 (0.47) | CYP17A1LCKTOP2ATOP2BHDAC3 | |
| SCHEMBL6627242 | 0.87 | CYP17A1 (0.47) | CYP17A1LCKTOP2ATOP2BHDAC3 | |
| SCHEMBL22469882 | 0.84 | KDM4E (0.55) | KDM4ELMNAALDH1A1HSD17B10MAPT | |
| SCHEMBL31568470 | 0.84 | KDM4E (0.55) | KDM4ELMNAALDH1A1HSD17B10MAPT | |
| SCHEMBL4309080 | 0.83 | KDM4E (0.50) | KDM4ELMNAALDH1A1HSD17B10MAPT | |
| SCHEMBL89282 | 0.82 | KMT2A (0.45) | ALDH1A1CYP17A1LCKMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257400-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230257400-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-08-17 | — | — | US | disclosed |
| EP-3778602-B1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-4163284-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20210171546-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210171547-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2021-06-10 | — | — | US | disclosed |
| EP-3778602-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10787463-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| EP-3325482-B1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3653628-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3325483-B1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10370389-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190112320-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2019-04-18 | — | — | US | disclosed |
| US-9873708-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873708-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170050985-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170051011-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170051011-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050985-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787463-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | GABRA3, GABRA5, GABRB3 | KDM4E 2896/4885LMNA 809/4885ALDH1A1 2133/4885 |
| US-20210171547-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRB3 | KDM4E 2896/4885LMNA 809/4885ALDH1A1 2133/4885 |
| US-20210171546-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRB3 | KDM4E 2896/4885LMNA 809/4885ALDH1A1 2133/4885 |
| US-20230257400-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRB3 | KDM4E 2896/4885LMNA 809/4885ALDH1A1 2133/4885 |
| US-10370389-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | GABRA3, GABRA5, GABRB3 | KDM4E 2896/4885LMNA 809/4885ALDH1A1 2133/4885 |
| US-20190112320-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRB3 | KDM4E 2896/4885LMNA 809/4885ALDH1A1 2133/4885 |
| US-20170050985-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRB3 | KDM4E 2896/4885LMNA 809/4885ALDH1A1 2133/4885 |
| US-20170051011-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRB3 | KDM4E 2896/4885LMNA 809/4885ALDH1A1 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.